Tag: anti-BCMA

Home / anti-BCMA

Categories

CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA

Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple...
anti-bcma

Scan the code